Purdue Pharma is in a plan-stage Chapter 11 posture, with the case path now centered on a twelfth amended reorganization plan that classifies creditor and stakeholder recoveries across 18 classes under the debtors’ proposed restructuring framework in the Twelfth Amended Joint Chapter 11 PlanDkt. 3726.
The case began when Purdue Pharma L.P. and affiliated debtors commenced Chapter 11 after a restructuring effort had to proceed alongside extensive opioid-related litigation and operating needs. The Chapter 11 Voluntary PetitionDkt. 1 opened the lead case, and the first-day declaration described a pharmaceutical enterprise with approximately 700 employees, regulated manufacturing and clinical-trial operations, and significant litigation-administration demands, including legal-cost advancement for current and former employees involved in approximately 2,600 civil actions in the Lowne First Day DeclarationDkt. 3.
The debtors entered Chapter 11 with substantial liquidity, reporting approximately $1.36 billion in cash as of September 13, 2019, but the first-day story was not a conventional cash-crisis filing. Purdue sought to preserve business continuity while maintaining payroll, benefits, cash-management systems, and essential vendor relationships in a heavily regulated supply chain where replacing certain vendors could require 12 to 24 months of regulatory review; the declaration identified up to $7.7 million of critical-vendor claims tied to operations, supply chain, clinical-trial, and foreign vendors in the .
The operative restructuring direction is therefore a reorganization rather than a sale process or liquidation path reflected in the supplied record. The available context does not include a confirmation order, effective date, or upcoming hearing calendar, so the present high-signal posture is that Purdue’s case has moved from first-day stabilization into a mature plan process anchored by the Twelfth Amended Joint Chapter 11 PlanDkt. 3726, with no source-backed near-term milestone provided here.
